[Coronary thrombolytic agents and their characteristics].
Yoshinaga
M
M
Cardiovascular Center, Osaka Red Cross Hospital.
Kambara
H
H
D016255:Anistreplase / Q000008:administration & dosage / Q000737:chemistry; D002986:Clinical Trials as Topic; D003331:Coronary Vessels; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000737:chemistry; D006801:Humans; D007261:Infusions, Intra-Arterial; D009203:Myocardial Infarction / Q000188:drug therapy / Q000503:physiopathology; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000737:chemistry; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000737:chemistry; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000737:chemistry; D014654:Vascular Patency
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D016255:Anistreplase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase